Search results
Results from the WOW.Com Content Network
Pages in category "Drugs developed by Pfizer" The following 200 pages are in this category, out of approximately 240 total. This list may not reflect recent changes .
When used appropriately, formularies can help manage drug costs imposed on the insurance policy. [7] However, for drugs that are not on formulary, patients must pay a larger percentage of the cost of the drug, sometimes 100%. Formularies vary between drug plans and differ in the breadth of drugs covered and costs of co-pay and premiums.
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
[[Category:Dermatology templates]] to the <includeonly> section at the bottom of that page. Otherwise, add <noinclude>[[Category:Dermatology templates]]</noinclude> to the end of the template code, making sure it starts on the same line as the code's last character.
Pfizer Inc (NYSE:PFE) is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand “Pfizer for All.” The move ...
Medication costs can be the selling price from the manufacturer, that price together with shipping, the wholesale price, the retail price, and the dispensed price. [3]The dispensed price or prescription cost is defined as a cost which the patient has to pay to get medicines or treatments which are written as directions on prescription by a prescribers. [4]
Pfizer has launched a cost-cutting program that targets savings of $4 billion annually by the end of 2024. It entails a one-time cost of around $3 billion and includes layoffs.
Pfizer's shares were up 2.6% at $29.30 in afternoon trading. Pfizer made the disclosure on Wednesday in a filing with the Securities and Exchange Commission. Pfizer rolls out another cost-cutting ...